Catalyst Pharmaceuticals (CPRX) Total Liabilities (2010 - 2026)

Catalyst Pharmaceuticals has reported Total Liabilities for 17 years, with the latest figure at $134.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 17.74% year-over-year to $134.9 million; the trailing twelve-month figure through Mar 2026 stood at $134.9 million (up 17.74% YoY), and the FY2025 full-year result was $149.7 million, up 20.95% from the prior year.
• Total Liabilities for Q1 2026 stood at $134.9 million, down from $149.7 million in the prior quarter.
• The five-year high for Total Liabilities was $149.7 million in Q4 2025, with the low at $26.2 million in Q2 2022.
• Historically, Total Liabilities has averaged $90.9 million across 5 years, with a median of $85.3 million in 2024.
• The largest YoY upside for Total Liabilities was 175.0% in 2023 against a maximum downside of 2.52% in 2023.
• Catalyst Pharmaceuticals' Total Liabilities stood at $75.2 million in 2022, then rose by 9.34% to $82.2 million in 2023, then jumped by 50.52% to $123.8 million in 2024, then increased by 20.95% to $149.7 million in 2025, then slipped by 9.88% to $134.9 million in 2026.
• The last three Total Liabilities figures came in at $134.9 million (Q1 2026), $149.7 million (Q4 2025), and $131.4 million (Q3 2025), per Business Quant data.